Published in Sex Transm Infect on April 06, 2011
Cervical Intraepithelial Neoplasm (CIN) in Women (Gardasil)(V501-015) | NCT00092534
Prevalence of plasmid-bearing and plasmid-free Chlamydia trachomatis infection among women who visited obstetrics and gynecology clinics in Malaysia. BMC Microbiol (2016) 1.42
Let's huddle to prevent a muddle: centrosome declustering as an attractive anticancer strategy. Cell Death Differ (2012) 1.17
Clinical trials of human papillomavirus vaccines and beyond. Nat Rev Clin Oncol (2013) 1.11
Association of Chlamydia trachomatis infection with redetection of human papillomavirus after apparent clearance. J Infect Dis (2013) 0.91
Chlamydia trachomatis and Genital Mycoplasmas: Pathogens with an Impact on Human Reproductive Health. J Pathog (2014) 0.86
Molecular detection of HPV and Chlamydia trachomatis infections in Brazilian women with abnormal cervical cytology. Am J Trop Med Hyg (2012) 0.86
The role of infectious agents in urogenital cancers. Infect Agent Cancer (2012) 0.85
Human papillomavirus genotypes distribution among Gabonese women with normal cytology and cervical abnormalities. Infect Agent Cancer (2016) 0.84
Multinucleation during C. trachomatis infections is caused by the contribution of two effector pathways. PLoS One (2014) 0.84
Does chlamydial infection increase the risk of cervical dysplasia? Sex Transm Infect (2011) 0.84
Association of Chlamydia trachomatis infection and herpes simplex virus type 2 serostatus with genital human papillomavirus infection in men: the HPV in men study. Sex Transm Dis (2013) 0.84
Are HPV vaccination services accessible to high-risk communities? A spatial analysis of HPV-associated cancer and Chlamydia rates and safety-net clinics. Cancer Causes Control (2013) 0.80
Human papillomavirus: what every provider should know. Am J Obstet Gynecol (2012) 0.78
Association of human papillomavirus, Neisseria gonorrhoeae and Chlamydia trachomatis co-infections on the risk of high-grade squamous intraepithelial cervical lesion. Am J Cancer Res (2016) 0.78
Cervical Microbiome and Cytokine Profile at Various Stages of Cervical Cancer: A Pilot Study. PLoS One (2016) 0.77
Incidence and persistence of carcinogenic genital human papillomavirus infections in young women with or without Chlamydia trachomatis co-infection. Cancer Med (2015) 0.75
Cervical cytopathological findings in Korean women with Chlamydia trachomatis, Mycoplasma hominis, and Ureaplasma urealyticum infections. ScientificWorldJournal (2014) 0.75
Prevalence of Chlamydia trachomatis endocervical infection in systemic lupus erythematosus patients and evaluation of the risk for HPV-induced lesions. Rheumatol Int (2012) 0.75
Human papillomavirus is a necessary cause of invasive cervical cancer worldwide. J Pathol (1999) 40.46
Quadrivalent vaccine against human papillomavirus to prevent high-grade cervical lesions. N Engl J Med (2007) 15.40
Quadrivalent vaccine against human papillomavirus to prevent anogenital diseases. N Engl J Med (2007) 12.17
Prophylactic quadrivalent human papillomavirus (types 6, 11, 16, and 18) L1 virus-like particle vaccine in young women: a randomised double-blind placebo-controlled multicentre phase II efficacy trial. Lancet Oncol (2005) 9.67
Serotypes of Chlamydia trachomatis and risk for development of cervical squamous cell carcinoma. JAMA (2001) 5.99
A cohort study of the risk of cervical intraepithelial neoplasia grade 2 or 3 in relation to papillomavirus infection. N Engl J Med (1992) 5.96
Human papillomavirus type distribution in 30,848 invasive cervical cancers worldwide: Variation by geographical region, histological type and year of publication. Int J Cancer (2011) 5.43
Efficacy of human papillomavirus-16 vaccine to prevent cervical intraepithelial neoplasia: a randomized controlled trial. Obstet Gynecol (2006) 4.33
Association of condom use, sexual behaviors, and sexually transmitted infections with the duration of genital human papillomavirus infection among adolescent women. Arch Pediatr Adolesc Med (2006) 1.81
Association of Chlamydia trachomatis with persistence of high-risk types of human papillomavirus in a cohort of female adolescents. Am J Epidemiol (2005) 1.67
A population-based prospective study of Chlamydia trachomatis infection and cervical carcinoma. Int J Cancer (2002) 1.43
Chlamydia trachomatis infection and persistence of human papillomavirus. Int J Cancer (2005) 1.39
Comprehensive analysis of Human Papillomavirus and Chlamydia trachomatis in in-situ and invasive cervical adenocarcinoma. Gynecol Oncol (2009) 1.19
Seroprevalence of human papillomaviruses and Chlamydia trachomatis and cervical cancer risk: nested case-control study. J Gen Virol (2007) 1.16
Prevalence and incidence of HPV genital infection in women. Sex Transm Dis (2009) 1.06
Cytologic findings in cervical chlamydial infection. Med Biol (1980) 1.03
Role of cervical dendritic cell subsets, co-stimulatory molecules, cytokine secretion profile and beta-estradiol in development of sequalae to Chlamydia trachomatis infection. Reprod Biol Endocrinol (2008) 0.91
Joint effects of different human papillomaviruses and Chlamydia trachomatis infections on risk of squamous cell carcinoma of the cervix uteri. Eur J Cancer (2004) 0.91
Quadrivalent vaccine against human papillomavirus to prevent anogenital diseases. N Engl J Med (2007) 12.17
Boceprevir for previously treated chronic HCV genotype 1 infection. N Engl J Med (2011) 12.09
Efficacy of quadrivalent HPV vaccine against HPV Infection and disease in males. N Engl J Med (2011) 11.09
A controlled trial of a human papillomavirus type 16 vaccine. N Engl J Med (2002) 10.58
Human papillomavirus genotype attribution in invasive cervical cancer: a retrospective cross-sectional worldwide study. Lancet Oncol (2010) 9.86
Prophylactic quadrivalent human papillomavirus (types 6, 11, 16, and 18) L1 virus-like particle vaccine in young women: a randomised double-blind placebo-controlled multicentre phase II efficacy trial. Lancet Oncol (2005) 9.67
Efficacy of a bivalent L1 virus-like particle vaccine in prevention of infection with human papillomavirus types 16 and 18 in young women: a randomised controlled trial. Lancet (2004) 8.09
A 9-valent HPV vaccine against infection and intraepithelial neoplasia in women. N Engl J Med (2015) 7.99
Genital human papillomavirus infection: incidence and risk factors in a cohort of female university students. Am J Epidemiol (2003) 7.35
Anal human papillomavirus infection and associated neoplastic lesions in men who have sex with men: a systematic review and meta-analysis. Lancet Oncol (2012) 6.05
High recurrence rates of bacterial vaginosis over the course of 12 months after oral metronidazole therapy and factors associated with recurrence. J Infect Dis (2006) 5.96
Use of Bakri balloon tamponade in the treatment of postpartum hemorrhage: a series of 50 cases from a tertiary teaching hospital. Acta Obstet Gynecol Scand (2012) 5.93
Condom use and the risk of genital human papillomavirus infection in young women. N Engl J Med (2006) 5.69
Overall efficacy of HPV-16/18 AS04-adjuvanted vaccine against grade 3 or greater cervical intraepithelial neoplasia: 4-year end-of-study analysis of the randomised, double-blind PATRICIA trial. Lancet Oncol (2011) 5.57
Human papillomavirus and Papanicolaou tests to screen for cervical cancer. N Engl J Med (2007) 5.57
The impact of quadrivalent human papillomavirus (HPV; types 6, 11, 16, and 18) L1 virus-like particle vaccine on infection and disease due to oncogenic nonvaccine HPV types in generally HPV-naive women aged 16-26 years. J Infect Dis (2009) 5.09
Once-daily valacyclovir to reduce the risk of transmission of genital herpes. N Engl J Med (2004) 5.04
Overview of human papillomavirus-based and other novel options for cervical cancer screening in developed and developing countries. Vaccine (2008) 4.82
HPV vaccine against anal HPV infection and anal intraepithelial neoplasia. N Engl J Med (2011) 4.69
Efficacy of human papillomavirus-16 vaccine to prevent cervical intraepithelial neoplasia: a randomized controlled trial. Obstet Gynecol (2006) 4.33
Should donors be allowed to give broad consent to future biobank research? Lancet Oncol (2006) 4.30
Impact of human papillomavirus (HPV)-6/11/16/18 vaccine on all HPV-associated genital diseases in young women. J Natl Cancer Inst (2010) 4.20
Both high and low levels of blood vitamin D are associated with a higher prostate cancer risk: a longitudinal, nested case-control study in the Nordic countries. Int J Cancer (2004) 4.10
Cross-protective efficacy of HPV-16/18 AS04-adjuvanted vaccine against cervical infection and precancer caused by non-vaccine oncogenic HPV types: 4-year end-of-study analysis of the randomised, double-blind PATRICIA trial. Lancet Oncol (2011) 3.98
Web-based recruiting for health research using a social networking site: an exploratory study. J Med Internet Res (2012) 3.82
Guidelines for human papillomavirus DNA test requirements for primary cervical cancer screening in women 30 years and older. Int J Cancer (2009) 3.64
The epidemiology of human papillomavirus infections. J Clin Virol (2005) 3.63
The impact of quadrivalent human papillomavirus (HPV; types 6, 11, 16, and 18) L1 virus-like particle vaccine on infection and disease due to oncogenic nonvaccine HPV types in sexually active women aged 16-26 years. J Infect Dis (2009) 3.55
Genital human papillomavirus infection in men: incidence and risk factors in a cohort of university students. J Infect Dis (2007) 3.48
Screening-preventable cervical cancer risks: evidence from a nationwide audit in Sweden. J Natl Cancer Inst (2008) 3.24
Virologic versus cytologic triage of women with equivocal Pap smears: a meta-analysis of the accuracy to detect high-grade intraepithelial neoplasia. J Natl Cancer Inst (2004) 3.20
Risk of female human papillomavirus acquisition associated with first male sex partner. J Infect Dis (2008) 3.19
Evaluation of genital sites and sampling techniques for detection of human papillomavirus DNA in men. J Infect Dis (2004) 3.18
Chapter 9: Clinical applications of HPV testing: a summary of meta-analyses. Vaccine (2006) 3.15
A review of clinical trials of human papillomavirus prophylactic vaccines. Vaccine (2012) 3.03
Etiologies of nongonococcal urethritis: bacteria, viruses, and the association with orogenital exposure. J Infect Dis (2005) 3.00
Human papillomavirus infection and cervical cytology in women screened for cervical cancer in the United States, 2003-2005. Ann Intern Med (2008) 2.98
Natural history of genital warts: analysis of the placebo arm of 2 randomized phase III trials of a quadrivalent human papillomavirus (types 6, 11, 16, and 18) vaccine. J Infect Dis (2009) 2.92
American Cancer Society Guideline for human papillomavirus (HPV) vaccine use to prevent cervical cancer and its precursors. CA Cancer J Clin (2007) 2.81
Ethical framework for previously collected biobank samples. Nat Biotechnol (2007) 2.81
Immunologic responses following administration of a vaccine targeting human papillomavirus Types 6, 11, 16, and 18. Vaccine (2006) 2.78
Human papillomavirus type 16 and 18 variants: race-related distribution and persistence. J Natl Cancer Inst (2006) 2.67
Induction of immune memory following administration of a prophylactic quadrivalent human papillomavirus (HPV) types 6/11/16/18 L1 virus-like particle (VLP) vaccine. Vaccine (2007) 2.64
Head and neck squamous cell cancer and the human papillomavirus: summary of a National Cancer Institute State of the Science Meeting, November 9-10, 2008, Washington, D.C. Head Neck (2009) 2.59
Development and duration of human papillomavirus lesions, after initial infection. J Infect Dis (2005) 2.51
Fall in human papillomavirus prevalence following a national vaccination program. J Infect Dis (2012) 2.51
A pooled analysis of continued prophylactic efficacy of quadrivalent human papillomavirus (Types 6/11/16/18) vaccine against high-grade cervical and external genital lesions. Cancer Prev Res (Phila) (2009) 2.42